AIM OF THE STUDY: A totally implantable venous access port (TIVAP) has become an essential prerequisite for many chemotherapy protocols. It is serving its purpose very well, but its use is not without complications. We are presenting our experience with these devices (TIVAPs). SUBJECTS AND METHODS: We retrospectively reviewed the totally implantable venous access ports in 81 patients at our hospital between January 2009 and March 2011 for long-term problems which include postoperative and follow-up problems, excluding the immediate complications which occur at the time of insertion. RESULTS: Catheter malfunction was the most common complication (9.87%, 0.40/1000 device-days of use/observation). Catheter-related bloodstream infections were present in 5 (6.17%) patients (0.25/1000 device-days of use/observation). The mean life of the catheter was 246 days. Only 11.1% ports required removal during the treatment period. Overall, patients either completed treatment (82.8%) or died (6.1%) while receiving treatment. CONCLUSION: TIVAPs provide safe and reliable vascular access for patients on chemotherapy but require utmost care by a dedicated team of trained medical professionals and paramedics experienced with the use of such ports, in order to minimize the complications and their continued use while administering treatment.
AIM OF THE STUDY: A totally implantable venous access port (TIVAP) has become an essential prerequisite for many chemotherapy protocols. It is serving its purpose very well, but its use is not without complications. We are presenting our experience with these devices (TIVAPs). SUBJECTS AND METHODS: We retrospectively reviewed the totally implantable venous access ports in 81 patients at our hospital between January 2009 and March 2011 for long-term problems which include postoperative and follow-up problems, excluding the immediate complications which occur at the time of insertion. RESULTS: Catheter malfunction was the most common complication (9.87%, 0.40/1000 device-days of use/observation). Catheter-related bloodstream infections were present in 5 (6.17%) patients (0.25/1000 device-days of use/observation). The mean life of the catheter was 246 days. Only 11.1% ports required removal during the treatment period. Overall, patients either completed treatment (82.8%) or died (6.1%) while receiving treatment. CONCLUSION: TIVAPs provide safe and reliable vascular access for patients on chemotherapy but require utmost care by a dedicated team of trained medical professionals and paramedics experienced with the use of such ports, in order to minimize the complications and their continued use while administering treatment.
Authors: Eric Voog; Loïc Campion; Pauline du Rusquec; Hugues Bourgeois; Julien Domont; Fabrice Denis; Eric Emmanuel; Olivier Dupuis; Gérard Ganem; Cedrik Lafont; Katell Le Du; Elena Pavluc; Yohan Pointreau; Sophie Roche; Laurence Juhel-Voog; Marie Zinger; Philippe Solal-Celigny Journal: Support Care Cancer Date: 2017-07-29 Impact factor: 3.603
Authors: Daniele Biacchi; Paolo Sammartino; Simone Sibio; Fabio Accarpio; Maurizio Cardi; Paolo Sapienza; Alessandro De Cesare; Joseph Maher Fouad Atta; Alessio Impagnatiello; Angelo Di Giorgio Journal: World J Surg Date: 2016-02 Impact factor: 3.352
Authors: Ahmad Awan; Bisma Ahsan; Hasan Iftikhar; Akbar Khan; Fasil Tiruneh; Yididia Bekele; Ankit Mahajan; Ahmed A Awan Journal: Cureus Date: 2017-07-11
Authors: Cesar Bustos; Aitziber Aguinaga; Francisco Carmona-Torre; Jose Luis Del Pozo Journal: Infect Drug Resist Date: 2014-02-18 Impact factor: 4.003